Related Experiment Video
Updated: Jun 25, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies
Jiaxu Zhang1, Marco Terreni2, Fang Liu3
1Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, UMR 8232, 4 Place Jussieu, Paris 75005, France; College of Life Sciences, Northwest University, Xi'an 710069, China.
Abstract:
Ganglioside GM3 is one of the most common membrane-bound glycosphingolipids. The over-expression of GM3 on tumor cells makes it defined as a tumor-associated carbohydrate antigen (TACA). The specific expression property in cancers, especially in melanoma, make it become an important target to develop anticancer vaccines or immunotherapies. However, in the manner akin to most TACAs, GM3 is an autoantigen facing with problems of low immunogenicity and easily inducing immunotolerance, which means itself only cannot elicit a powerful enough immune response to prevent or treat cancer. With a comparative understanding of the mechanisms that how immune system responses to the carbohydrate vaccines, this review summarizes the studies on the recent efforts to development GM3-based anticancer vaccines.
Insights
Ganglioside GM3, a tumor antigen, shows promise for cancer vaccines but has low immunogenicity. This review explores strategies to enhance GM3-based anticancer vaccine development for improved immune response.
Area of Science:
- Immunology
- Oncology
- Carbohydrate Chemistry
Background:
- Ganglioside GM3 is a common glycosphingolipid overexpressed on tumor cells, acting as a tumor-associated carbohydrate antigen (TACA).
- GM3's specific expression in cancers like melanoma makes it a target for anticancer vaccines and immunotherapies.
- However, GM3 is an autoantigen with low immunogenicity, often inducing immune tolerance, limiting its efficacy as a standalone vaccine.
Purpose of the Study:
- To review recent advancements in developing GM3-based anticancer vaccines.
- To understand the immune system's response mechanisms to carbohydrate vaccines.
- To address the challenges of low immunogenicity and immune tolerance associated with GM3.
Main Methods:
- Comparative analysis of immune responses to carbohydrate vaccines.
- Review of studies focusing on GM3-based vaccine development strategies.
- Examination of approaches to overcome GM3's inherent limitations.
Main Results:
- GM3 is a significant target for cancer immunotherapy, particularly in melanoma.
- Strategies are being developed to enhance the immunogenicity of GM3.
- Overcoming immune tolerance is crucial for effective GM3-based vaccines.
Conclusions:
- GM3-based vaccines hold potential for cancer treatment, but require optimization.
- Further research into enhancing immune responses against GM3 is necessary.
- Understanding immune mechanisms is key to successful GM3-targeted cancer immunotherapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy